ASH

ASH: Carfilzomib increases survival in relapsed multiple myeloma

ASH: Carfilzomib increases survival in relapsed multiple myeloma

Improved progression-free survival in relapsed multiple myeloma has been seen with the addition of carfilzomib to lenalidomide and dexamethasone therapy.

CAR cell engineering offers hope for patients with hard-to-treat blood disorders

By

The use of chimeric antigen receptor (CAR) cell engineering was described in several studies presented at the 2013 ASH Annual Meeting in New Orleans.

Advances in cell engineering improve prognosis of haploidentical stem cell transplantation

By

Genetically engineered cell therapies may bring hope to patients for whom standard treatments have been unsuccessful, according to two separate studies presented at the 2013 ASH Annual Meeting, in New Orleans, Louisiana.

Genetic driver of Waldenström macroglobulinemia identified

By

In nearly one-third of patients with Waldenström macroglobulinemia, the disease is switched on by a specific genetic mutation. A new drug that blocks the defective gene can arrest the disease in animal models, according to research reported at the 2013 ASH Annual Meeting, in New Orleans.

Age alone should not limit access to stem cell transplants for patients with MDS

By

Patients with myelodysplastic syndrome age 66 to 74 years did as well with stem cell transplantation as patients age 60 to 65 years. This research was presented at the 2013 ASH Annual Meeting, in New Orleans.

Drug induces morphologic, molecular, and clinical remissions in myelofibrosis

By

Imetelstat, a novel telomerase-inhibiting drug, has been found to induce morphologic, molecular, and clinical remissions in some patients with myelofibrosis, according to a new study. The results were presented at the 2013 ASH Annual Meeting, in New Orleans.

Bortezomib regimen improves stem cell transplantation outcomes

By

Adding bortezomib to standard preventive therapy for GVHD results in improved outcomes for patients receiving stem cell transplants from mismatched and unrelated donors, according to research presented at the 2013 ASH Annual Meeting, in New Orleans.

Targeted treatment reduces relapse in children with AML

By

Combining the monoclonal antibody gemtuzumab with standard chemotherapy significantly reduced the risk of relapse and increased rates of disease-free survival in pediatric patients with AML. Posttreatment relapse rates are a major indicator of potential for long-term survival in children with the disease.

Umbilical cord blood stem cells treat leukemia and lymphoma

Umbilical cord blood stem cells treat leukemia and lymphoma

By

Growing cord blood stem cells in a laboratory before transplanting them into patients with leukemia, lymphoma, and other blood cancers significantly improves survival, according to a new study.

Less painful drug delivery is safe and effective for pediatric leukemia patients

By

Children with acute lymphoblastic leukemia (ALL), the most common form of pediatric cancer, can safely receive intravenous infusions of a reformulated mainstay of chemotherapy that has been delivered via painful IM injection for more than 40 years, research suggests.

Drug-antibody pair has promising activity in non-Hodgkin lymphoma

By

A toxin linked to a targeted monoclonal antibody has shown compelling antitumor activity in patients with non-Hodgkin lymphomas (NHLs) who were no longer responding to treatment, according to a new report.

Ibrutinib may be a breakthrough for treatment of a rare lymphoma

Interim results confirmed the "unprecedented" single-agent activity of ibrutinib in relapsed or refractory mantle cell lymphoma.

Pomalidomide extends survival in multiple myeloma

A new immunomodulatory drug under FDA review significantly increased survival in persons with multiple myeloma, including older patients.

Study drug makes marrow transplant possible in relapsed leukemia

The final data from a phase II study confirmed the high degree of activity of quizartinib in persons with acute myeloid leukemia.

Ibrutinib appears safe, effective against chronic lymphocytic leukemia

Ibrutinib, which targets the Bruton's tyrosine kinase to combat chronic lymphocytic leukemia, showed promising results in two phase II studies.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs